



PATENT

1PW

Case Docket No. ACADIA.031A

Date: July 15, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Weiner, et al.
Appl. No. : 10/761,787
Filed : January 21, 2004
For : USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Examiner : Unknown
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 15, 2004

(Date)

Sam K. Tahmassebi, Reg. No. 45,151

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with seven (7) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant	:	Weiner, et al.
App. No.	:	10/761,787
Filed	:	January 21, 2004
For	:	USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Examiner	:	Unknown
Group Art Unit	:	1614

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing seven references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

EXPLANATION UNDER 37 C.F.R. § 1.98(a)(3)(i)

The relevance of French Patent FR 51 F is that it depicts N-desmethylozapine in Table 2, Example 9 and contains a statement on page 5, left hand column, that the International Search Authority stated disclosed a tablet preparation that was "a neuroleptic useful in the treatment of psychosis."

Appl. No. : 10/761,787
Filed : January 21, 2004

Docket No. ACADIA.031A
Customer No. 20,995

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this Information Disclosure Statement.


Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 15, 2004

By: Sam K. Tahmassebi
Sam K. Tahmassebi
Registration No. 45,151
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\REM\REM-1487.DOC:sad
071504

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.031A	APPLICATION NO. 10/761,787
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Weiner, et al.	
		FILING DATE January 21, 2004	GROUP 1614



FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1	WO 02/060870	08/08/02	WIPO				
	2	FR 51	04/06/64	France				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	3	Özdemir, V., et al., "CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia," <i>Journal of Clinical Psychopharmacology</i> , 21:4(398-407), August 2001.						
	4	Spina, E., et al., "Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia," <i>International Clinical Psychopharmacology</i> , 13:141-145, 1998.						
	5	Sur, C., et al., "N-desmethylozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 100:23(13674-13679) Nov. 11, 2003.						
	6	Weigmann, H., et al., "Does the pharmacologically active N-demethylated metabolite of clozapine pass the blood-brain barrier?" <i>Pharmacopsychiatry</i> , and "20 th Symposium of AGNP, Nuremberg, Germany," 30:5(233), September 1997.						
	7	Young, C., et al., "Effects of Desmethylozapine on Fas Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine Metabolite," <i>Neuropsychopharmacology</i> , 19:1(99-103) 1998.						

S:\DOCS\REM\REM-1486.DOC:sad
071504

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	